{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:23:18Z","timestamp":1776090198980,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Review of utilization and efficacy of eribulin in Australian metastatic breast cancer (MBC) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective review of consecutive MBC patients treated with eribulin in tertiary Australian BC centers. Key inclusion criteria included eribulin administration in nonclinical trial setting from October 2014 onwards, known duration of MBC systemic treatments administered and known follow\u2010up date after eribulin. Cox regression model was used to assess survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Study population comprised 266 patients from eight centers treated between October 2014 and May 2018. Median age at time of MBC diagnosis was 54 years with 18% of patients having de novo MBC. Seventy\u2010six percent had hormone receptor positive (HRp) disease, 19% triple negative (TN) and 5% HER2\u2010positive. CNS involvement was present in 36% of patients. Eribulin was most frequently given as third\u2010line chemotherapy (36%), with no prior anthracycline exposure in 14% of total population. Eribulin was given more frequently as \u2264third\u2010line chemotherapy than\u00a0&gt;\u00a0third\u2010line in patients with TN disease, \u2265 two metastatic sites or CNS disease. Median overall survival (OS) from eribulin administration was 9.2 (95% CI [8.0, 10.3]) months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Similar efficacy was demonstrated for eribulin when given in the first\u2010line to beyond the fifth line of chemotherapy in all subtypes of MBC.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13576","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T15:38:56Z","timestamp":1618501136000},"page":"201-208","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia"],"prefix":"10.1111","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2135-2286","authenticated-orcid":false,"given":"Arlene","family":"Chan","sequence":"first","affiliation":[{"name":"Breast Cancer Research Centre\u2010WA and Curtin University  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-1467","authenticated-orcid":false,"given":"Christopher","family":"Lomma","sequence":"additional","affiliation":[{"name":"Breast Cancer Research Centre\u2010WA  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HuiJun","family":"Chih","sequence":"additional","affiliation":[{"name":"School of Public Health Curtin University, Bentley  Perth Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Blackely","sequence":"additional","affiliation":[{"name":"Maroondah and Box Hill Hospitals  Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Woodward","sequence":"additional","affiliation":[{"name":"Mater Misericordiae Ltd\/ University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne","family":"Tsoi","sequence":"additional","affiliation":[{"name":"St John of God Hospital \u2010 Subiaco and Murdoch  Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Cheong","sequence":"additional","affiliation":[{"name":"Ashford Cancer Centre Research  Adelaide, Southern Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Chipman","sequence":"additional","affiliation":[{"name":"\u201cVictorian Breast and Oncology Care\u201d at St Vincent's Private Hospital  East Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Redfern","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital  Western Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"e_1_2_15_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4892"},{"key":"e_1_2_15_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3144-y"},{"key":"e_1_2_15_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw203"},{"key":"e_1_2_15_6_1","first-page":"19","article-title":"Brain metastases from breast cancer and response to treatment with eribulin: A case series","volume":"9","author":"Chang AY","year":"2015","journal-title":"Breast Cancer (Auckl)"},{"issue":"24","key":"e_1_2_15_7_1","first-page":"Abstract nr P6\u2010","article-title":"Impact of the number of prior chemotherapy regimens on overall survival among subjects with locally recurrent or metastatic breast cancer treated with eribulin mesylate: Results from the phase III EMBRACE study","volume":"70","author":"Blum JL","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"e_1_2_15_8_1","first-page":"Abstract nr P5\u2010","article-title":"Utilization and outcomes of eribulin in triple negative metastatic breast cancer: Real\u2010world findings","volume":"77","author":"Kish JK","year":"2017","journal-title":"Cancer Res"},{"key":"e_1_2_15_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-018-9906-x"},{"key":"e_1_2_15_10_1","first-page":"231","article-title":"Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first\u2010line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: Results from a Phase II, single\u2010arm, multicenter study","volume":"8","author":"Puhalla S","year":"2016","journal-title":"Breast Cancer"},{"key":"e_1_2_15_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.10.001"},{"key":"e_1_2_15_12_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0773"},{"key":"e_1_2_15_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0324"},{"key":"e_1_2_15_14_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.8748"},{"key":"e_1_2_15_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1673-3"},{"key":"e_1_2_15_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000493"},{"key":"e_1_2_15_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32402"},{"key":"e_1_2_15_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8091010"},{"key":"e_1_2_15_19_1","first-page":"77","article-title":"Subgroup analyses from a phase 3, open\u2010label, randomized study of Eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer","volume":"10","author":"Twelves C","year":"2016","journal-title":"Breast Cancer (Auckland)"},{"key":"e_1_2_15_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4778-y"},{"key":"e_1_2_15_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.80"},{"key":"e_1_2_15_22_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0936"},{"key":"e_1_2_15_23_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.35109"},{"key":"e_1_2_15_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000176"},{"key":"e_1_2_15_25_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212506"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13576","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T23:46:27Z","timestamp":1692834387000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/ajco.13576"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13576","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"assertion":[{"value":"2021-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}